Condition(s):Breast Cancer Metastatic
Principal Investigator:Tolaney, Sara, M
Site Research Nurse(s):Agius, Christine,
Roche, Kathleen, A.
To determine whether amcenestrant per overall survival (os) improves progression free
survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in
participants with metastatic or locally advanced breast cancer
- To compare the overall survival in the 2 treatment arms
- To assess the objective response rate in the 2 treatment arms
- To evaluate the disease control rate in the 2 treatment arms
- To evaluate the clinical benefit rate in the 2 treatment arms
- To evaluate the duration of response in the 2 treatment arms
- To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in
the 2 treatment arms
- To evaluate the pharmacokinetics of amcenestrant as single agent
- To evaluate health-related quality of life in the 2 treatment arms
- To compare the overall safety profile in the 2 treatment arms
Inclusion criteria :
- 18 years or older.
- Histological or cytological diagnosis of adenocarcinoma of the breast.
- Locally advanced not amenable to radiation therapy or surgery in a curative intent,
and/or metastatic disease.
- Estrogen receptor(ER) positive status.
- Human epidermal growth factor receptor 2 negative status.
- Participants must have received no more than 1 prior chemotherapeutic or 1 targeted
therapy regimen for advanced/metastatic disease.
- In the main study, a prior treatment with a Cyclin-dependent kinase 4 and 6(CDK 4/6)
inhibitor is mandatory if this treatment is approved and can be reimbursed for this
participant. The percentage of participants without previous CDK 4/6 inhibitor will be
capped to 20%. In the Chinese extension cohort, previous treatment with a CDK 4/6
inhibitor will not be mandatory, and there will be no limitation to the number of
participants naïve to CDK4/6 inhibitor.
- Participants must present a secondary endocrine resistance to endocrine therapy
defined as: progression while on endocrine therapy after at least 6 months of
treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy
but after the first 2 years, or with a relapse within 12 months after completing
adjuvant endocrine therapy.
- Male or Female.
- Eastern Cooperative Oncology Group performance status =>2.
- Medical history or ongoing gastrointestinal disorders potentially affecting the
absorption of amcenestrant. Participants unable to swallow normally and to take
- Participant with any other cancer. Adequately treated basal cell or squamous cell skin
cancer or in situ cervical cancer or any other cancer from which the participant has
been disease free for greater than 3 years are allowed.
- Severe uncontrolled systemic disease at screening .
- Participants with known brain metastases that are untreated, symptomatic or require
therapy to control symptoms.
- Prior treatment with mammalian target of rapamycin inhibitors or any other selective
estrogen receptor degrader(SERD) compound, except fulvestrant if stopped for at least
3 months before randomization.
- Treatment with drugs that have the potential to inhibit Uridine'5
Diphospho-Glucuronosyl Transferase(UGT) less than 2 weeks before randomization.
- Treatment with strong Cytochrome P450 (CYP)3A inducers within 2 weeks before
- Ongoing treatment with drugs that are sensitive substrate of organic anion
transporting polypeptide 1B1/B3(OATP1B1/B3) (asunaprevir, atorvastatin, bosentan,
danoprevir, fexofenadine, glyburide, nateglinide, pitavastatin, pravastatin,
replaglinide, rosuvastatin, and simvastatin acid).
- Treatment with anticancer agents (including investigational drugs) less than 3 weeks
- Inadequate hematological, coagulation, renal and liver functions.
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
Protocol #: 19-391